roche glp 1 drug Roche, trailing in obesity, showcases new data for GLP-1 shot Roche Enters the GLP-1 Obesity

GLP-1 medications prescribing trends from 20182024 reveal shifts in semaglutide and tirzepatide use for type 2 diabetes and obesity.

Within professional research environments, Retatrutide is frequently examined for its role in

Northwestern Medicine cardiologist Dr

Online health and wellness company Hims & Hers posted a $92 million loss in the first quarter as it shifts its business from selling compounded weight loss drugs to branded GLP-1 medications.

Link to full post: GLP-1 Drugs, Digital Health & Obesity Trends in 2026Overweight and obesity are driving a booming digital health market through telehealth, wearables, and new pharma-to-consumer models.I've been reporting on this space in my #Trends report since March 2024two years ago (Navigating Obesity Care in the Digital Age)